- Complete blood count, liver function tests, serum urea, and electrolytes: At baseline, then monthly for three months, and subsequently every three months

- Screen for latent tuberculosis before initiating therapy with a chest X-ray and Mantoux test

- Screening for viral markers before initiating therapy

- dsDNA- screen yearly

- Signs/symptoms/worsening of heart failure

- Signs and symptoms of hypersensitivity reactions

- Signs/symptoms of malignancy, including periodic skin examination.

- Newer studies recommend maintaining therapeutic drug monitoring for serum concentrations of adalimumab at between 5 to 8 mg/ml and subsequent maintenance and tapering of the drug guided by these levels.